Simple Summary Even though the presently employed biomarkers in the detection and
management of multiple myeloma are demonstrating encouraging results, the mortality …

Simple Summary Monitoring the response to treatment in hematologic malignancies is
essential in defining the best way to optimize patient management. In general, achieving a …

Structural chromosomal changes including copy number aberrations (CNAs) are a major
feature of multiple myeloma (MM), however their evolution in context of modern biological …

Monitoring measurable residual disease (MRD) is crucial to assess treatment response in
Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring …

Liquid biopsy, particularly circulating tumor DNA (ctDNA), has drawn a lot of attention as a
non-or minimal-invasive detection approach for clinical applications in patients with cancer …

The need for sensitive monitoring of minimal/measurable residual disease (MRD) in multiple
myeloma emerged as novel therapies led to deeper responses. Moreover, the potential …

Background and aims Multiple myeloma (MM), a neoplasm of plasma cells (PCs), is a highly
heterogeneous disease with multifocal dissemination throughout the body. Minimal residual …

Il Mieloma Multiplo (MM) è una patologia neoplastica delle cellule B caratterizzata dalla
proliferazione di più cloni di plasmacellule portatrici di diverse anomalie genomiche. Il MM …

Abstract Introduction: Multiple Myeloma, a rare and historically deemed untreatable blood
cancer, continues to pose a significant health challenge. While the standard of care for …

A recent NGS study in patients with MDS demonstrated that molecular as well as cytogenetic
abnormalities in cfDNA from peripheral blood mirror the profile in bone marrow. Such results …